Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.50 |
| ▸ | LTA4H | P09960 | 4/20 | 0.50 |
| ▸ | CHKA | P35790 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325275 | 1.00 | MC4R (0.52) | MC4RFADS1GRM2LTA4HCHKA | |
| SCHEMBL2893311 | 0.96 | GRM2 (0.56) | MC4RFADS1GRM2LTA4HCHKA | |
| SCHEMBL13086078 | 0.96 | GRM2 (0.56) | MC4RFADS1GRM2LTA4HCHKA | |
| SCHEMBL2901469 | 0.88 | FADS1 (0.49) | FADS1GRM2LTA4HCHKANPC1 | |
| SCHEMBL2901466 | 0.88 | FADS1 (0.49) | FADS1GRM2LTA4HCHKANPC1 | |
| SCHEMBL4328587 | 0.87 | DRD4 (0.54) | FADS1GRM2 | |
| SCHEMBL4328591 | 0.87 | DRD4 (0.54) | FADS1GRM2 | |
| SCHEMBL8227799 | 0.86 | LTA4H (0.53) | FADS1GRM2LTA4HNPC1RAB9A | |
| SCHEMBL5478198 | 0.86 | GRM2 (0.58) | FADS1GRM2LTA4HCHKA | |
| SCHEMBL2898095 | 0.86 | GRM2 (0.58) | FADS1GRM2LTA4HCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | MC4R 438/4885FADS1 4353/4885GRM2 3/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | MC4R 438/4885FADS1 4353/4885GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.